<DOC>
	<DOCNO>NCT00003679</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether doxorubicin plus docetaxel effective doxorubicin plus cyclophosphamide breast cancer . PURPOSE : Randomized phase III trial compare effectiveness doxorubicin combination either docetaxel cyclophosphamide treat woman previously untreated , advance , inflammatory breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy ( response rate ) toxicity doxorubicin combination either docetaxel cyclophosphamide primary therapy regimens patient locally advance inflammatory breast cancer . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center operability . Patients randomize one two treatment arm . Arm I : Patients receive docetaxel IV follow doxorubicin IV every 3 week . Arm II : Patients receive doxorubicin IV cyclophosphamide IV every 3 week . Patients receive maximum 6 course treatment absence disease progression unacceptable toxicity . Patients undergo surgery ( operable ) follow chemotherapy ( node positive ) , radiation therapy , oral tamoxifen 5 year ( discretion investigator estrogen receptor-negative patient ) . Patients follow 12 , 18 , 24 month , annually least 5 year . PROJECTED ACCRUAL : A total 350 patient ( 175 per arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously untreated locally advanced inflammatory breast cancer Potentially operable disease Tumor least 3 cm diameter No metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 60 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : PT aPTT normal Bilirubin normal ( except patient benign congenital hyperbilirubinemia ) AST/ALT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN No active hepatitis B C Liver biopsy normal ( positive serology hepatitis B C ) Renal : Creatinine normal Cardiovascular : Adequate cardiac function No active cardiac disease Other : Not pregnant Fertile patient must use effective contraception No serious medical psychiatric disease No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No prior therapy breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>